Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 12:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Zolpidem, 5 mg Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

NCT02839200
View directory record Official record
Conditions
Insomnia Disorder
Interventions
ACT-541468 5 mg, ACT-541468 10 mg, ACT-541468 25 mg, Zolpidem, Placebo 1, Placebo 2
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Santa Monica, California • Upland, California • Brandon, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 24, 2026, 12:24 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia

NCT04009577
View directory record Official record
Conditions
Insomnia
Interventions
LEM 5 mg, LEM 10 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
17
States / cities
Glendale, Arizona • Sacramento, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 24, 2026, 12:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers

NCT00716521
View directory record Official record
Conditions
Methodology Study
Interventions
placebo, zolpidem
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 23, 2009 · Synced Sep 24, 2026, 12:24 AM EDT
Completed Phase 2 Interventional

Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder

NCT03056053
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Zolpidem
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Santa Monica, California • Atlanta, Georgia • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 24, 2026, 12:24 AM EDT
Recruiting Phase 3 Interventional

Sleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients

NCT07336277
View directory record Official record
Conditions
Orthopedic Trauma, Sleep Quality
Interventions
Standard Postoperative Care, Zolpidem, Melatonin, Sleep Hygiene Education, Actigraph GT3X-BT Actigraph
Other · Drug · Dietary Supplement + 2 more
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 24, 2026, 12:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Characteristics of Sleep Patterns in Young Adults With and Without Insomnia

NCT00177216
View directory record Official record
Conditions
Sleep Disorders
Interventions
Zolpidem, Escitalopram, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
20 Years to 50 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Sep 24, 2026, 12:24 AM EDT
Recruiting Phase 4 Interventional

A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia

NCT07542756
View directory record Official record
Conditions
Insomnia, Insomnia Disorder, Chronic Insomnia, Chronic Insomnia Disorder
Interventions
Sleep Hygiene Education, Melatonin IR, 3 mg, Melatonin IR, 5 mg, Diphenhydramine, 25 mg, Diphenhydramine, 50 mg, Doxepin, 3 mg, Doxepin, 6 mg, Trazodone, 50 mg, Trazodone, 100 mg, Placebo, Zolpidem, 5 mg, Zolpidem, 10 mg
Other · Dietary Supplement · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 24, 2026, 12:24 AM EDT
Terminated Not applicable Interventional Results available

Sleep and Endometrial Cancer

NCT00936598
View directory record Official record
Conditions
Sleep, Endometrial Neoplasms, Pain
Interventions
zolpidem, sugar pill
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Sep 24, 2026, 12:24 AM EDT
Completed Phase 4 Interventional Results available

Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia

NCT03774810
View directory record Official record
Conditions
Insomnia, Insomnia Chronic
Interventions
Zolpidem tartrate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 24, 2026, 12:24 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study

NCT04273776
View directory record Official record
Conditions
Performance Enhancing Product Use
Interventions
Suvorexant 10 mg, Zolpidem, Placebos
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 39 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 24, 2026, 12:24 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Two Contrasting Interventions for Sleep Management

NCT01804036
View directory record Official record
Conditions
Primary Insomnia, Secondary Insomnia
Interventions
Zolpidem, Mind-Body Bridging
Drug · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
17 Years to 40 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Colorado Springs, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 24, 2026, 12:24 AM EDT
Completed Phase 4 Interventional Results available

Improving Sleep Quality in Heart Failure

NCT03307005
View directory record Official record
Conditions
Sleep Disturbance, Heart Failure
Interventions
Zolpidem Tartrate, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 79 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 24, 2026, 12:24 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

SM-1 vs. an Active Comparator in A Model of Transient Insomnia

NCT04396327
View directory record Official record
Conditions
Transient Insomnia
Interventions
SM-1, Active Comparator
Drug
Lead sponsor
Sequential Medicine Ltd
Industry
Eligibility
25 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Sep 24, 2026, 12:24 AM EDT
Recruiting Phase 2 Interventional

Trial of Zolpidem for Sleep in Children With Autism

NCT05540574
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Zolpidem, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 24, 2026, 12:24 AM EDT
Completed Phase 3 Interventional Results available

SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.

NCT03331042
View directory record Official record
Conditions
Transient Insomnia
Interventions
SM-1, D+Z, D+L, Placebo
Drug
Lead sponsor
Sequential Medicine Ltd
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 24, 2026, 12:24 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia

NCT00784875
View directory record Official record
Conditions
Primary Insomnia, Secondary Insomnia
Interventions
LY2624803, Placebo, zolpidem
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Sep 24, 2026, 12:24 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)

NCT02783729
View directory record Official record
Conditions
Insomnia
Interventions
Lemborexant, Lemborexant-matched placebo, Zolpidem tartrate, Zolpidem-matched placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
60
States / cities
Jasper, Alabama • Glendale, Arizona • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 24, 2026, 12:24 AM EDT
Recruiting Phase 4 Interventional

The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion

NCT05746143
View directory record Official record
Conditions
Spine Fusion, Lumbar Spine Degeneration, Pain, Postoperative, Lumbar Spine Spondylosis
Interventions
Zolpidem Tartrate 10 mg, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 24, 2026, 12:24 AM EDT
Completed Phase 4 Interventional Results available

Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing

NCT00156533
View directory record Official record
Conditions
Insomnia, Primary Insomnia, Psychophysiologic Insomnia
Interventions
Zolpidem, Sugar Pill
Drug
Lead sponsor
University of Rochester
Other
Eligibility
25 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 24, 2026, 12:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older

NCT03008447
View directory record Official record
Conditions
Healthy Subjects
Interventions
LEM5, LEM10, ZOL, PBO
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 24, 2026, 12:24 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

NCT03375203
View directory record Official record
Conditions
Insomnia Disorders
Interventions
Placebo, JNJ-42847922, 5 mg, JNJ-42847922, 10 mg, JNJ-42847922, 20 mg, Zolpidem
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 24, 2026, 12:24 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

NCT03436745
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Zolpidem, ECG
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 24, 2026, 12:24 AM EDT